Background {#Sec1}
==========

The digestive system, which consists of the gastrointestinal tract, liver, pancreas, and biliary tree, functions in digestion, absorption, and metabolism and affects the basis of life. Various diseases, including cancer, inflammatory disease, infection, stones, and ulcers, are studied under the context of gastroenterology. While innovative drugs against *Helicobacter pylori* \[[@CR1]\], hepatitis C virus \[[@CR2]\], and inflammatory bowel disease (IBD) \[[@CR3]\] have recently been developed, there are still unmet needs in this field, including in acute and chronic liver failure and refractory IBDs. Cell therapy may fulfill these unmet needs, and cell therapies using mesenchymal stem cells (MSCs) have become a major focus in many fields \[[@CR4]\]. MSCs are reported to have multiple functions, especially anti-fibrosis and anti-inflammatory effects are focused in acute and chronic liver failure and refractory IBDs. Furthermore, MSCs have low immunogenicity, can expand easily, and can be obtained from medical waste, suggesting their potential to expand regenerative medicine for the treatment of liver diseases and IBDs.

In this paper, we review the current status of clinical trials using autologous/allogeneic MSCs in liver diseases and IBDs.

Characteristics of MSCs {#Sec2}
=======================

MSCs have recently received attention as potential cell sources for cell therapy due to their ease of expansion and wide range of functions. MSCs can be obtained from not only bone marrow but also medical wastes, such as adipose tissue, umbilical tissue, and dental pulp. MSCs are positive for the common markers CD73, CD90, and CD105; however, they are negative for the endothelial marker CD31 and hematopoietic marker CD45 \[[@CR4]--[@CR7]\]. The expansion of MSCs in culture is relatively easy, and under appropriate conditions, MSCs have trilineage differentiation (osteogenic, chondrogenic, and adipogenic) potential. The effects of MSCs are broadly divided into two mechanisms: (1) recruited MSCs differentiate into functional cells to replace damaged cells, permitting the treatment of bone and cartilage damage; and (2) in response to inflammatory cytokines, MSCs help prepare the microenvironment by producing immunoregulatory factors that modulate the progression of inflammation by affecting dendritic cells, B cells, T cells, and macrophages. MSCs also produce a large amount of cytokines, chemokines, and growth factors, including exosomes, which stimulate angiogenesis, prevent apoptosis, block oxidation reactions, promote remodeling of the extracellular matrix (ECM), and induce the differentiation of tissue stem cells \[[@CR4], [@CR7], [@CR8]\]. These latter mechanisms can be applied for many diseases, including liver disease and IBSs. Some studies have reported that the effects of MSCs are determined by host conditions, such as inflammation stage and the use of immunosuppressants.

Although the behaviors of MSCs after administration have been analyzed, and some studies have shown that MSCs migrate to the injured site, MSC behaviors in humans have not been fully elucidated. Some studies have reported that MSCs disappear within a few weeks and do not remain long in the target tissue \[[@CR5]\]. Recent studies have reported that only culture-conditioned medium or exosomes induce treatment effects, suggesting that the trophic effect is the most important effect of MSCs \[[@CR9]--[@CR11]\]. Another important characteristic of MSCs is that they generally have low immunogenicity. MSCs have no antigen-presenting properties and do not express major histocompatibility complex class II or costimulatory molecules; thus, injection of autologous or allogeneic MSCs has been employed in clinical studies. Allogeneic MSC therapy has the potential to expand MSC therapy to many patients \[[@CR4], [@CR7]\].

Clinical trials using MSCs {#Sec3}
==========================

Since MSCs can be obtained relatively easily and have multiple functions, more than 680 clinical trials are ongoing according to ClinicalTrials.gov (<https://clinicaltrials.gov/>); most of these studies are phase I or II trials evaluating the use of MSCs in bone/cartilage, heart, neuron, immune/autoimmune, diabetes/kidney, lung, liver, and gastrointestinal fields. These studies aim to elucidate the safety/effectiveness of MSCs in the treatment of various diseases. In liver diseases, 40 trials are registered, most of which target liver cirrhosis or acute liver diseases (Table [1](#Tab1){ref-type="table"}) \[[@CR12]--[@CR21]\]. The MSCs used in clinical trials of the liver are derived from the bone marrow (55%), umbilical cord tissue (35%), and adipose tissue (8%). Approximately 50% of MSCs are allogeneic. Additionally, while the major administration route is the peripheral blood, approximately 40% of cases are treated via the hepatic artery, reflecting the fact that hepatologists and radiologists often use catheters to treat hepatocellular carcinoma through the hepatic artery \[[@CR22], [@CR23]\] (Fig. [1](#Fig1){ref-type="fig"}).Table 1Clinical trials in liver diseasesNo.Start yearCell sourceAutologous/allogeneicAdministration routeNumber of cells infusedEtiologyNumber of patientsFollow-up periodPhaseStudy designClinicalTrials.gov identifierStatusResultReferences12013Bone marrowAutologousPeripheral veinUnknownLC2048 weeksPhase 1--2Non-randomized, single group assignment, open labelNCT01877759Unknown22009Bone marrowAutologousHepatic artery5 × 106 cells/patient, 2 timesLC (alcohol)1124 weeksPhase 2Non-randomized, single group\
assignment, open labelNCT01741090UnknownHistological improvement. Improvement in Child- Pugh score. Decrease in TGFβ1, collagen type I,\
and α-SMA32009Bone marrowAutologousPeripheral vein1.0 × 106/kgLC2524 weeksUnknownNon-randomized, single group assignment, open labelNCT01499459UnknownImprovement in Alb and MELD scores.1342014Umbilical cordAllogeneicPeripheral vein4.0 × 107/patient, 4 timesLC320144 weeksPhase 1--2Non-randomized, parallel assignment, open labelNCT01573923Unknown52016Adipose tissueAutologousPortal vein or hepatic artery1.0 × 106/kg via peripheral vein, 3 times or 3.0 × 106/kg via hepatic artery, 3 timesLC (HCV)548 weeksPhase 1--2Non-randomized, single group assignment, open labelNCT02705742Recruiting62007Bone marrowAutologousPeripheral or portal vein30--50 × 106/patientLC824 weeksPhase 1--2Randomized, single group assignment, single blindNCT00420134CompletedImprovement in liver function and MELD scores.1472016Bone marrowAllogeneicPeripheral vein2.0 × 106/kg, 4 timesACLF3096 weeksPhase 1Randomized, parallel assignment, double blind (subject, caregiver, investigator)NCT02857010Recruiting82009Umbilical cordAllogeneicPeripheral vein5.0 × 105/kg, 3 timesACLF (HBV)4396 weeksPhase 1--2Randomized, parallel assignment, double blind (subject, caregiver)NCT01218464UnknownImprovement in liver function and MELD scores.1592011Bone marrowAllogeneicPeripheral vein2.0 × 105/kg, 4 times or 1.0 × 106/kg, 4 times or 5.0 × 106/kg, 4 timesLiver failure (HBV)12048 weeksPhase 2Randomized, parallel assignment, open labelNCT01322906Unknown102010Umbilical cordAllogeneicUnknownUnknownLC2048 weeksPhase 1--2Randomized, parallel assignment, open labelNCT01342250Completed112012Bone marrowAllogeneicHepatic arteryUnknownLC (Alcohol)4096 weeksPhase 2Randomized, parallel assignment, open labelNCT01591200Completed122012Umbilical cordAllogeneicPeripheral vein1.0 × 105/kg, 4 timesLiver failure (HBV)12048 weeksPhase 1--2Randomized, parallel assignment, open labelNCT01724398Unknown132016Bone marrowAutologousPortal vein2.0 × 106/kgLC4024 weeksPhase 1--2Non-randomized, parallel assignment, open labelNCT02943889Not yet recruiting142009Umbilical cordAllogeneicPortal vein or hepatic arteryUnknownLC20048 weeksPhase 1--2Randomized, parallel assignment, single blind (subject)NCT01233102Suspended152009Bone marrowAutologousPortal veinUnknownLC (HBV)6048 weeksPhase 2Non-randomized, parallel assignment, open labelNCT00993941Unknown162010Umbilical cordAllogeneicHepatic arteryUnknownLC504 weeksPhase 1--2Randomized, parallel assignment, open labelNCT01224327Unknown172013Bone marrowAutologousHepatic artery1.0 × 106/kgLC3012 weeksPhase 3Non-randomized, single group assignment, open labelNCT01854125Enrolling by invitation182012Umbilical cordAllogeneicHepatic artery1.0 × 106/kgLC (HBV)24048 weeksPhase 1--2Randomized, parallel assignment, open labelNCT01728727Unknown192013Umbilical cord or bone marrowAllogeneicPeripheral vein1.0 × 105/kg, 1.0 × 106/kg or 1.0 × 107/kg, 8 timesLiver failure (HBV)21072 weeksPhase 1--2Randomized, parallel assignment, open labelNCT01844063Recruiting202016Umbilical cordAllogeneicPeripheral vein4 or 8 timesACLF (HBV)26152 weeksPhase 2Randomized, parallel assignment, open labelNCT02812121Not yet recruiting212010Menstrual bloodAllogeneicPeripheral vein1.0 × 106/kg, 4 timesLC5048 weeksPhase 1--2Randomized, single group assignment, open labelNCT01483248Enrolling by invitation222008Bone marrowAutologousHepatic arteryUnknownLC5096 weeksPhase 2Randomized, parallel assignment, single blind (subject)NCT00976287Unknown232012Bone marrowAutologousHepatic artery5 × 107/patient, 1 time or 2 timesLC (alcohol)7224 weeksPhase 2Randomized, parallel assignment, open labelNCT01875081CompletedHistological improvement. Improvement in AST, ALT, ALP, γ-GTP, Child-Pugh score, and MELD score.16242014Bone marrowAutologousPeripheral veinUnknownLC1024 weeksPhase 1Non-randomized, single group assignment, open labelNCT02327832Recruiting252005Bone marrowAutologousHepatic artery3.4 × 108/patientLiver failure (HBV)158192 weeksPhase 1--2Case control, retrospectiveNCT00956891CompletedImprovement in Alb, T-Bil, PT, and MELD score.262009Umbilical cordAllogeneicPeripheral vein5.0 × 105/kg, 3 timesLC4548 weeksPhase 1--2Randomized, parallel assignment, open labelNCT01220492UnknownImprovement in Alb, T-Bil, and MELD score.\
Reduction of ascites.17272010Bone marrowAutologousPortal vein1.4--2.5 × 108/patient, 2 timesLC248 weeksPhase 1Non-randomized, single group assignment, open labelNCT01454336CompletedTransient improvement in MELD scores.18282007Bone marrowAutologousPeripheral vein(1.2--2.95 × 108) 1.95 × 108/patientLC2748 weeksUnknownRandomized, parallel assignment, double\
blind (subject, outcomes assessor)NCT00476060UnknownNo beneficial effect.19292011Bone marrowAllogeneicHepatic artery and peripheral artery1.0 × 106/kg (5.0 × 107 cells via the hepatic artery and the remaining cells via the peripheral vein)Wilson's disease1024 weeksUnknownNon-randomized, single group assignment, open labelNCT01378182Completed302016Umbilical cord or bone marrowAllogeneicPortal vein or hepatic artery2.0 × 107/patient, 4 timesLC2048 weeksPhase 1Non-randomized, single group assignment, open labelNCT02652351Recruiting312016Bone marrowAutologousHepatic artery5 × 107/patient, 1 time or 2 timesLC (alcohol)50144 weeksPhase 2Randomized, parallel assignment, open labelNCT02806011Enrolling by invitation322011Umbilical cordAllogeneicPeripheral vein1.0 × 106/kg, 3 timesLiver failure (AIH)10096 weeksPhase 1--2Randomized, parallel assignment, open labelNCT01661842Unknown332009Adipose tissueAutologousUnknownUnknownLC624 weeksPhase 1Non-randomized, single group assignment, open labelNCT00913289Terminated342012Adipose tissueAutologousHepatic arteryUnknownLC44 weeksUnknownNon-randomized, single group assignment, open labelNCT01062750Completed352016Umbilical cordAllogeneicLobe5.0 × 108/patientLC4096 weeksPhase 1--2Randomized, parallel assignment, double blind (subject, outcomes assessor)NCT02786017Recruiting362011Bone marrowUnknownPeripheral vein5.0--50 × 106/kgLC (PBC)2096 weeksPhase 1Randomized, parallel assignment, open labelNCT01440309Unknown372011Umbilical cordAllogeneicPeripheral vein5.0 × 105/kg, 3 timesLC (PBC)748 weeksPhase 1--2Randomized, parallel assignment, open labelNCT01662973UnknownImprovement in Alb, T-Bil, and MELD score. Reduction of ascites.20382010Bone marrowAllogeneicPortal vein or hepatic arteryUnknownLiver failure (HBV)6048 weeksPhase 2Non-randomized, parallel assignment, open labelNCT01221454Unknown392010Bone marrowAllogeneicPortal vein or hepatic arteryUnknownLC6048 weeksPhase 2Non-randomized, parallel assignment, open labelNCT01223664Unknown402010Bone marrowAutologousHepatic artery(0.25--1.25 × 106) 0.75 × 106/patientLC (HBV)3924 weeksPhase 2--3Non-randomized, parallel assignment, open labelNCT01560845UnknownDecrease in Th-17 cells, RORγt, IL-17, TNF-α, and IL-6. Increase in Tregs and Foxp3.21*LC* liver cirrhosis, *ACLF* acute-on-chronic liver failure, *HBV* hepatitis B virus, *HCV* hepatitis C virus, *AIH* autoimmune hepatitis, *PBC* primary biliary cholangitis, *MELD* Model for End-Stage Liver Disease, *AST* aspartate transaminase, *ALT* alanine transaminase, *ALP* alkaline phosphatase, *γ-GTP* gamma-glutamyl transpeptidase, *Alb* albumin, *T-bill* total bilirubin, *PT* prothrombin time, *PC* protein C, *ROR* RAR-related orphan receptor, *Foxp3* forkhead box *P3*, IL interleukin, *Th* T helper, *SMA* smooth muscle actin, *TGF* transforming growth factor, *TNF* tumor necrosis factor Fig. 1Summary of clinical trials in liver diseases

In IBDs, 26 trials are registered (Table [2](#Tab2){ref-type="table"}), 23 of which are investigating the use of MSCs in Crohn's disease (CD), and 3 of which are investigating the use of MSCs in ulcerative colitis (UC) \[[@CR24]--[@CR33]\]. More than 60% of trials are employing allogeneic MSCs, and in CD, more than 40% of the trials are evaluating intralesional injection into the fistula, which is the major and refractory complication of CD (Fig. [2](#Fig2){ref-type="fig"}).Table 2Clinical trials in inflammatory bowel diseasesNo.Start yearCell sourceAutologous/allogeneicAdministration routeNumber of cells infusedDiseasesNumber of patientsFollow-up periodPhaseStudy designClinicalTrials.gov identifierStatusResultReferences12006Bone marrowAllogeneicPeripheral vein8 × 106 cells/kg, 2 times or 2 × 106 cells/kg, 2 timesCrohn's disease104 weeksPhase 2Randomized, parallel assignment, open labelNCT00294112Completed22007Bone marrowAllogeneicPeripheral veinTotal of 6 × 108 cells/patient, 4 times or total of 12 × 108\
cells/patient, 4 timesCrohn's disease9824 weeksPhase 3Randomized, parallel assignment, double blindNCT00543374Completed32010Adipose tissueAutologousUnknownUnknownFistulizing Crohn's disease153 yearsPhase 1--2Non-randomized, single group assignment, open labelNCT01157650Completed42015Umbilical cordAllogeneicPeripheral veinUnknownCrohn's disease321 yearPhase 1--2Randomized, parallel assignment, open labelNCT02445547Completed52012Bone marrowAllogeneicPeripheral vein2 × 108 cells/patient, more than 4 timesCrohn's disease114 weeksPhase 1--2Non-randomized, single group assignment, open labelNCT01510431Completed62010Bone marrowAllogeneicPeripheral vein2 × 106 cells/kg, 4 timesCrohn's disease156 weeksPhase 2Non-randomized, single group assignment, open labelNCT01090817CompletedImprovement in CDAI, AQoL score. Decrease in CRP. Endoscopic improvement2472012Bone marrowAutologousPeripheral vein2 × 106 cells/kg, 5 × 106 cells/kg, or 1 × 107 cells/kgCrohn's disease161 yearPhase 1Non-randomized, single group assignment, open labelNCT01659762Completed82010Bone marrowAllogeneicIntralesional1 × 107 cells/patient, 3 × 107 cells/patient, or 9 × 107 cells/patientFistulizing Crohn's disease2112 weeksPhase 1--2Randomized, parallel assignment, double blindNCT01144962CompletedLocal treatment with MSCs showed promotion of fistula healing. Lower MSC dose seemed superior.2592009Adipose tissueAutologousIntralesional3 × 107 cells/patient (in the event of incomplete closure at 8 weeks, a second injection was given that contained 1.5 times more cells than the f irst)Fistulizing Crohn's disease438 weeksPhase 1Non-randomized, single group assignment, open labelNCT00992485CompletedLocal treatment with MSCs showed promotion of fistula healing.26102010Adipose tissueAllogeneicIntralesional2 × 107 cells/patient (in the event of incomplete closure\
at 12 weeks, an additional 4 × 107 cells were administered)Fistulizing Crohn's disease2424 weeksPhase 1--2Non-randomized, single group assignment, open labelNCT01372969CompletedLocal treatment with MSCs showed promotion of fistula healing.27112009Adipose tissueAutologousIntralesional1 × 107 cells/patient, 2 × 107 cells/patient, or 4 × 107\
cells/patientFistulizing Crohn's disease104 weeksPhase 1Non-randomized, single group assignment, open labelNCT00992485CompletedLocal treatment with MSCs showed promotion of fistula healing. All patients with complete healing showed a sustained effect.28122009Adipose tissueAllogeneicIntralesional2 × 107 cells/patient (in the event of incomplete closure at 12 weeks, an additional 4 × 107 cells were administered)Fistulizing Crohn's disease1012 weeksPhase 1--2Non-randomized, single group assignment, open labelNCT00999115CompletedLocal treatment with MSCs showed promotion of fistula healing; 60% of patients achieved complete healing.29132009Adipose tissueAutologousIntralesional1 × 107 cells/cm^2^Fistulizing Crohn's disease438 weeksPhase 2Non-randomized, single group assignment, open labelNCT01011244CompletedIn most cases, complete closure after initial treatment was well-sustained over a 24-month period.30142007Bone marrowAllogeneicPeripheral veinTotal of 6 × 108 cells/patient, 4 times or total of 1.2 × 109 cells/patient, 4 timesCrohn's disease3304 weeksPhase 3Randomized, parallel assignment, double blindNCT00482092Active152012Adipose tissueAllogeneicIntralesional1.2 × 108 cells/patientFistulizing Crohn's disease21224 weeksPhase 3Randomized, parallel assignment, double blindNCT01541579ActiveLocal treatment with MSCs showed promotion of fistula healing.31162010Bone marrowAllogeneicPeripheral vein2 × 10\^8 cells/patient, 3 timesCrohn's disease120180 daysPhase 3Non-randomized, single group assignment, open labelNCT01233960Active172015Adipose tissueAutologousIntralesionalUnknownFistulizing Crohn's disease1062 weeksPhase 2Non-randomized, single group assignment, open labelNCT02403232Recruiting182013Bone marrowAutologousIntralesionalUnknownFistulizing Crohn's disease1016 weeksPhase 1Randomized, parallel assignment, single blindNCT01874015Recruiting192015Adipose tissueAllogeneicPeripheral vein5 × 107 cells/patient, 7.5 × 107 cells/patient, or 1 × 108 cells/patientCrohn's disease94 weeksPhase 1Non-randomized, single group assignment, open labelNCT02580617Recruiting202013Umbilical cordAllogeneicPeripheral vein5 × 107 cells/patient or 1 × 108 cells/patientCrohn's disease2412 weeksPhase 1--2Non-randomized, single group assignment, open labelNCT02000362Recruiting212013Adipose tissueAutologousIntralesional2 × 107 cells/patientFistulizing Crohn's disease202--24 monthsPhase 1Non-randomized, single group assignment, open labelNCT01915927Recruiting22UnknownBone marrowAutologousPeripheral vein1--2 × 106 cells/kgCrohn's disease106 weeksPhase 1Unknown----Three patients showed clinical response (decrease in CDAI).Three patients required surgery due to disease worsening.32232016Bone marrowAllogeneicIntralesional2 × 107 cells/patientFistulizing Crohn's disease207, 10, 16 monthsPhase 1Non-randomized, single group assignment, open labelNCT02677350Not yet recruiting242015Umbilical cordAllogeneicPeripheral vein1 × 106 cells/kg, 3 timesUlcerative colitis3024 weeksPhase 1--2Randomized, parallel assignment, single blindNCT02442037Recruiting252015Adipose tissueAllogeneicThrough a colonoscope6 × 107 cells/patientUlcerative colitis812 weeksPhase 1--2Non-randomized, single group assignment, open labelNCT01914887Unknown262015Umbilical cordAllogeneicFirst: peripheral vein, second: superior mesenteric arteryFirst: 3.8 ± 1.6 × 107 cells/patient, second: 1.5 × 107 cells/patientUlcerative colitis8012 weeksPhase 1--2Non-randomized, single group assignment, open labelNCT01221428UnknownDecrease in the median Mayo score and histology score. Improvement in IBDQ scores.33*CD* Crohn's disease, *CDAI* Crohn's Disease Activity Index, *AQoL* The Assessment of Quality of Life, *CRP* C-reactive protein, *IBDQ* Inflammatory Bowel Disease Questionnaire Fig. 2Summary of clinical trials in inflammatory bowel diseases

Clinical trials in liver diseases {#Sec4}
=================================

Background of liver diseases {#Sec5}
----------------------------

Although the liver has high regenerative capacity, acute liver damage caused by viruses, drugs, alcohol, and autoimmune diseases, or chronic liver damage caused by hepatitis B or C virus, alcohol, non-alcoholic steatohepatitis (NASH), autoimmune hepatitis, and primary biliary cholangitis often cause liver failure \[[@CR34]\]. The liver has a variety of functions, including metabolism of protein, sugar, and fat; detoxification; production of coagulation factors; and production of bile. Thus, during liver failure, several symptoms, including jaundice, edema, ascites, hepatic encephalopathy, and increased bleeding, can appear at the same time, resulting in life-threatening disease. In addition, during liver failure caused by chronic liver disease, accumulated liver fibrosis (i.e., liver cirrhosis) can cause portal hypertension, which often induces the varices, and long-term liver damage can cause gene abnormalities, leading to liver cancers. The ultimate therapy for liver failure is liver transplantation; however, only a small portion of patients with liver failure can receive liver transplantation due to the shortage of donor organs, invasiveness of operations, and economic reasons \[[@CR35]\]. Revolutionary treatments, such as interferon-free treatment for hepatitis C and providing information regarding the importance of the daily lifestyle to prevent alcoholic liver disease and NASH, can potentially decrease the liver diseases; however, unmet needs to treat advanced liver failure will continue.

Advanced acute liver failure and chronic liver failure (liver cirrhosis) can be good targets for cell therapy. Since 2003, Terai et al. initiated autologous bone marrow cell infusion (ABMi) therapy against decompensated liver cirrhosis and confirmed the improvement of liver fibrosis and liver function \[[@CR36]--[@CR38]\]. However, due to the invasiveness of liver transplantation in patients with liver failure, minimally invasive procedures using specific cells, such as MSCs and macrophages \[[@CR39]--[@CR41]\], are now being developed, with a focus on MSCs. In the next section, we will describe recent reported results using MSCs registered at ClinicalTrials.gov.

Effects of MSC therapy in liver disease from published papers {#Sec6}
-------------------------------------------------------------

Animal experiments have shown that MSCs can have anti-apoptotic \[[@CR42]\] and antioxidant effects in hepatocytes \[[@CR43]\], and antifibrotic \[[@CR44], [@CR45]\], angiogenic \[[@CR46]\], and immunosuppressive effects in T cells, macrophages, and dendritic cells \[[@CR8]\]. In human clinical trials, all reports have shown that MSC injection is safe. Although the effects of cell therapy are not uniform, the majority of therapies have some beneficial effects; in contrast, in a few reports, treatment effects were not observed. For example, Kantarcioglu et al. \[[@CR13]\] and Mohamadnejad et al. \[[@CR19]\] injected bone marrow-derived MSCs into patients with liver cirrhosis and did not observe treatment effects. However, Kharaziha et al. \[[@CR14]\] reported phase I--II clinical trials using autologous bone marrow-derived MSCs against liver cirrhosis with a variety of etiologies, and improvement of liver function was confirmed. Jang et al. and Suk et al. \[[@CR12], [@CR16]\] reported a pilot study and a phase II study using autologous bone marrow-derived MSCs injected through the hepatic artery against alcoholic liver cirrhosis, and improvement of histological liver fibrosis and liver function was confirmed. Xu et al. \[[@CR21]\] reported trials using autologous bone marrow-derived MSCs against hepatitis B virus-associated cirrhosis and confirmed the improvement of liver function, the decrease of Th17 cells, and the increase of regulatory T cells. Xhang et al. \[[@CR17]\] and Wang et al. \[[@CR20]\] reported trials using allogeneic umbilical cord-derived MSCs in patients with chronic hepatitis B having decompensated liver cirrhosis and primary biliary cirrhosis, respectively. They confirmed improvement of liver function, particularly reduced ascites and recovery of biliary enzymes, respectively. Shi et al. \[[@CR15]\] reported a trial investigating acute or chronic liver failure associated with hepatitis B virus and confirmed that MSCs significantly increased survival rates. From these reports, MSCs appeared to improve liver function; however, additional trials are needed to confirm these effects and to elucidate the mechanisms in more detail.

Clinical trials in IBDs {#Sec7}
=======================

Background of IBDs {#Sec8}
------------------

IBDs are chronic inflammatory disorders, including UC and CD. The pathogenesis of IBD is thought to be highly complex due to several factors, such as environmental factors, genetic predisposition, and inflammatory abnormalities \[[@CR47]\]. UC is characterized by inflammation of the mucosal membrane of the colon continued from the rectum. Type 2 T helper cell (Th2) cytokine profile is associated with the pathogenesis of UC. In contrast, CD is a segmental, transluminal disorder that can arise within the entire gastrointestinal tract from the mouth to the anus. Th1 cells are associated with the pathogenesis of CD \[[@CR48]\]. Furthermore, a recent report showed that Th17 cells are present in both UC and CD. Thus, mucosal CD4+ T cells are key mediators of the driving response \[[@CR49]\]. Macrophages that produce tumor necrosis factor (TNF)-α have also been reported to be relevant in IBD. Imbalances in other cytokines, such as interleukin (IL)-1β, IL-6, IL-8, IL-10, IL-12, IL-17, IL-23, and transforming growth factor-β (TGF-β), are also detected during diseases \[[@CR48]\]. Recent advancements in the development of drugs for IBD include drugs targeting TNF and new candidate drugs, such as antibodies against IL-6 \[[@CR50]\] and IL-12/23 \[[@CR51]--[@CR53]\], small molecules including Janus kinase inhibitors \[[@CR54]\], antisense oligonucleotides against SMAD7 mRNA \[[@CR55]\], and inhibitors of leukocyte trafficking to intestinal sites of inflammation \[[@CR56], [@CR57]\]. However, some patients will fail to respond to current medical options, immunosuppressive agents, and anti-TNF biologicals. MSCs may be an effective option in these patients \[[@CR9], [@CR49]\]. In the next section, we will describe recently reported results using MSCs registered in ClinicalTrials.gov.

Effects of MSC therapy in IBD from published papers {#Sec9}
---------------------------------------------------

Eight CD trials and one UC trial have been published in ClinicalTrials.gov. Six papers describing CD are on trials treating fistula, and two papers are trials for luminal CD. Molendijk et al. \[[@CR25]\] reported improved healing of refractory perianal fistulas using allogeneic bone marrow-derived MSCs. They administered these allogeneic MSCs locally and concluded that injection of 3 × 10^7^ MSCs appeared to promote the healing of perianal fistula. Panes et al. \[[@CR31]\] reported a phase III randomized, double-blind, parallel-group, placebo-controlled study of complex perianal fistula using expanded allogeneic adipose-derived MSCs and confirmed the safety of the MSCs and the healing effects of MSCs on the fistula. Duijvestein et al. \[[@CR32]\] reported a phase I study of refractory luminal CD using autologous bone marrow-derived MSCs and confirmed the safety and feasibility of MSC therapy. Forbes et al. \[[@CR24]\] reported a phase II study using allogeneic bone marrow-derived MSCs for luminal CD refractory to biologic therapy. They administered 2 × 10^6^ cells/kg weekly for 4 weeks and found that allogeneic MSCs reduced the CD activity index (CDAI) and CD endoscopic index of severity (CDEIS) scores in patients with luminal CD refractory to biologic therapy. Hu et al. \[[@CR33]\] reported a phase I/II study for severe UC using umbilical cord-derived allogeneic MSCs by combination injection through the peripheral blood and superior mesenteric artery with a 7-day interval. They confirmed the safety of MSCs and alleviation of diffuse and deep ulcer formation and severe inflammatory mucosa by MSCs.

Safety of the MSC therapy {#Sec10}
=========================

MSC therapy is associated with some concerns, such as adverse events related to infusion, tumor formation during the treatment of liver cirrhosis, and long-term observations of tumor formation. Regarding adverse events related to the infusion, Lalu et al. performed a meta-analysis of the safety of MSCs in clinical trials and showed that autologous and allogeneic MSC therapies were related to transient fever but not infusion toxicity, organ system complications, infection, death, and malignancies (Table [2](#Tab2){ref-type="table"}) \[[@CR5]\]. Regarding tumor formation during the treatment of liver cirrhosis, Peng et al. reported that no severe adverse events or no significant differences in tumor formation were detected compared with those in the control group during autologous bone marrow-derived MSC therapy for liver cirrhosis \[[@CR58]\]. Regarding long-term observations of tumor formation derived from MSCs, Bahr et al. reported recent autopsy data from patients in a clinical trial of graft-versus-host disease (GvHD) who received MSC therapy between 2002 and 2007 and revealed no ectopic tissues, neoplasms, or donor-derived DNA \[[@CR6]\].

Conclusions {#Sec11}
===========

Many clinical trials of autologous and allogeneic MSCs have aimed to elucidate the effects and mechanisms of MSCs. MSCs can expand easily and can be obtained from medical waste, suggesting their applications in regenerative medicine for the treatment of liver diseases and IBDs. Recently, limitations of MSCs have been reported. For example, therapeutic effects were not long term and were affected by inflammatory condition \[[@CR59], [@CR60]\]. Thus, the results of ongoing clinical studies will be expected to provide further insights.
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